288. 自己免疫性後天性凝固因子欠乏症 Autoimmune acquired coagulation factor deficiency Clinical trials / Disease details

臨床試験数 : 206 / 薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21

7 trials found

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05500807 (ClinicalTrials.gov)	November 1, 2022	12/8/2022	Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A	Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A	Von Willebrand Disease, Type 3;Concomitant VWD and Hemophilia	Drug: Emicizumab	Bleeding and Clotting Disorders Institute Peoria, Illinois	Genentech, Inc.	Recruiting	2 Years	90 Years	All	40	Phase 1	United States
2	NCT05345197 (ClinicalTrials.gov)	August 31, 2022	18/4/2022	Emicizumab in Patients With Acquired Hemophilia A	Emicizumabin Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial ...	Acquired Hemophilia A	Drug: emicizumab	University of Washington	Genentech, Inc.	Recruiting	18 Years	N/A	All	51	Phase 2	United States
3	NCT04567511 (ClinicalTrials.gov)	September 1, 2021	29/7/2020	Hemlibra in Mild Hemophilia A	Prospective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia ...	Factor VIII Deficiency, Congenital	Drug: Emicizumab	Indiana Hemophilia &Thrombosis Center, Inc.	Genentech, Inc.	Recruiting	5 Years	45 Years	Male	40	Phase 4	United States
4	EUCTR2019-004430-42-AT (EUCTR)	22/06/2021	22/04/2021	Evaluation of the effect of emicizumabin patients suffering from acute bleeds with previously no fam ...	Emicizumabin Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial ...	Acquired Hemophilia A (AHA) MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acqui ...	Trade Name: Hemlibra ® INN or Proposed INN: Emicizumab Other descriptive name: RO5534262 EMICIZUMAB	GWT-TUD GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	47	Phase 2	Austria;Germany
5	NCT04188639 (ClinicalTrials.gov)	March 23, 2021	4/12/2019	Emicizumab in Acquired Hemophilia A	Emicizumabin Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial ...	Hemophilia A, Acquired	Drug: Emicizumab Injection	GWT-TUD GmbH	Hoffmann-La Roche;Hannover Medical School	Completed	18 Years	N/A	All	47	Phase 2	Austria;Germany
6	EUCTR2019-004430-42-DE (EUCTR)	25/01/2021	20/11/2020	Evaluation of the effect of emicizumabin patients suffering from acute bleeds with previously no fam ...	Emicizumabin Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial ...	Acquired Hemophilia A (AHA) MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acqui ...	Trade Name: Hemlibra ® INN or Proposed INN: Emicizumab Other descriptive name: RO5534262 EMICIZUMAB	GWT-TUD GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	47	Phase 2	Austria;Germany
7	JPRN-JapicCTI-205151	15/6/2020	07/02/2020	PHASE III STUDY OF EMICIZUMAB IN PATIENTS WITH ACQUIRED HEMOPHILIA A (AGEHA)	A MULTICENTER, OPEN-LABEL, NON-RANDOMIZED, PHASE III STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMAC ...	Acquired hemophilia A	Intervention name : emicizumab (ACE910, RO5534262) INN of the intervention : emicizumab Dosage And admi ...	Chugai Pharmaceutical Co., Ltd.	NULL	complete	18		BOTH	11	Phase 3	Japan

First Previous1Next Last